Conflict of interest statement: Declaration of interests NAR has received 
personal fees from Bristol-Myers Squibb, Genentech, Roche, MedImmune, 
AstraZeneca, and Merck. TES has received research grant support from 
Bristol-Myers Squibb and personal fees from Genentech, Eli Lilly, Celgene, and 
Boehringer Ingelheim. SJA has received research grant support from MedImmune, 
and personal fees from Bristol-Myers Squibb, MedImmune, and AstraZeneca. LH has 
received research grant support from Astellas, has served as a non-paid 
consultant to Bayer and Xcovery, and has received personal fees from 
Bristol-Myers Squibb, Merck, Clovis, Helix Bio, and Genentech. HL has received 
personal fees from Bristol-Myers Squibb and Merck, and non-financial support 
from Bristol-Myers Squibb and Roche. BM has served as a consultant to 
Bristol-Myers Squibb and on advisory boards for Merck Sharp & Dohme. GAO has 
received research grant support from Bristol-Myers Squibb, Pfizer, 
GlaxoSmithKline, New Link Genetics, Genentech, and Boehringer Ingelheim, and has 
received personal fees from Genentech and Boehringer Ingelheim. DRG has received 
research grant support from Bristol-Myers Squibb. BPL has received personal fees 
from Eli Lilly, Genentech, Pfizer, Biodesix, and Boehringer Ingelheim. GZ has 
received personal fees from Bristol-Myers Squibb. JW has received research 
grants from Boehringer Ingelheim, Novartis, Pfizer, Roche, and Bayer, and has 
served on advisory boards for and received lecture fees from Bristol-Myers 
Squibb, AstraZeneca, Boehringer Ingelheim, Clovis, Novartis, Pfizer, Roche, and 
Merck Sharp and Dohme. PJS has received personal fees, non-financial support, 
and support for clinical studies from Roche. FC has received personal fees from 
Bristol-Myers Squibb. CC has served as a consultant to Bristol-Myers Squibb, 
Merck, and Roche. RS has received research grant support and honoraria from and 
has served on advisory boards for Bristol-Myers Squibb. RMH has served on 
advisory boards for Bristol-Myers Squibb. CTH, CB, and BJL are employed by and 
own stock in Bristol-Myers Squibb. SSR has received research grant support and 
personal fees from Bristol-Myers Squibb and has received personal fees from 
Amgen, AstraZeneca, Aveo, Boehringer Ingelheim, Celgene, Genentech, Eli Lilly, 
and Novartis. SJA, DRG, AD, and SSR have received funding from the National 
Institutes of Health (USA). The other authors declare no competing interests.